Building cognitive reserve helps delay memory and thinking decline regardless of genetic or childhood markers

By SharpBrains | August 30, 2022

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing time­ly brain news and a few fun brain teasers to test your per­cep­tu­al and cog­ni­tive skills. #1. Study: Build­ing cog­ni­tive reserve helps delay mem­o­ry and think­ing decline regard­less of genet­ic or child­hood mark­ers “While our child­hood can influ­ence our mem­o­ry and think­ing skills lat­er in life,…

Read More

Digital therapeutics pioneer Akili Interactive Labs goes public, raising $150M+; trades down 49% first day

By SharpBrains | August 23, 2022

Akili Inter­ac­tive is the lat­est com­pa­ny to go pub­lic via SPAC deal (Boston Busi­ness Jour­nal): Boston’s Akili Inter­ac­tive Labs Inc. is the lat­est Mass­a­chu­setts-based com­pa­ny to go pub­lic after com­plet­ing a reverse merg­er — in a year of mar­ket tur­moil that saw few local firms pass­ing the thresh­old between pri­vate and pub­lic sta­tus. Shares of…

Read More

FDA clears first videogame to be prescribed to kids with ADHD: EndeavorRx by Akili Interactive Labs

By SharpBrains | June 18, 2020

In a land­mark deci­sion, FDA green­lights a video game for kids with ADHD (STAT): The Food and Drug Admin­is­tra­tion on Mon­day for the first time gave a green light to a game-based ther­a­peu­tic: a video game meant to be pre­scribed to kids with ADHD. The game, known as Endeav­or­Rx and devel­oped by Boston-based Akili Inter­ac­tive Labs,…

Read More

Large study finds positive yet mixed results from Akili’s digital therapeutic for kids with ADHD

By SharpBrains | February 25, 2020

__ Full pub­li­ca­tion of piv­otal tri­al data out­lines Akil­i’s case for FDA reg­u­la­tion (Mobi­Health­News): “A full tran­script of STARS-ADHD — the piv­otal tri­al of Akili Interactive’s video game-like pedi­atric atten­tion deficit treat­ment — has been pub­lished in The Lancet Dig­i­tal Health jour­nal, pro­vid­ing onlook­ers a clear view of data fuel­ing the dig­i­tal ther­a­peu­tic company’s pending…

Read More

How to address privacy, ethical and regulatory issues: Examples in cognitive enhancement, depression and ADHD

By SharpBrains | July 23, 2019

? How to address pri­va­cy, eth­i­cal and reg­u­la­to­ry issues: Exam­ples in cog­ni­tive enhance­ment, depres­sion and ADHD from Sharp­Brains We hope you enjoy this slid­edeck sup­port­ing a great ses­sion at the 2019 Sharp­Brains Vir­tu­al Sum­mit: The Future of Brain Health (March 7–9th).  Full record­ings are avail­able for pur­chase here. 1–2.30pm. How to address pri­va­cy, eth­i­cal and reg­u­la­to­ry issues: Examples…

Read More

10+ pioneers confirmed to Speak @ 2019 SharpBrains Virtual Summit (May 7–9th)

By SharpBrains | February 19, 2019

_______________ We are proud to announce the first wave of con­firmed Speak­ers to share their inno­v­a­tive work and insights at the 2019 Sharp­Brains Vir­tu­al Sum­mit: The Future of Brain Health, to be held May 7–9th, 2019: Dr. Tom Insel, Co-founder and Pres­i­dent of Mind­strong Health Dr. Ainslie Hatch, Direc­tor of Dig­i­tal Ther­a­peu­tics at Otsu­ka Phar­ma­ceu­ti­cal David…

Read More